- Benzinga•15 hours ago
Brean Capital assumes coverage of Nektar Therapeutics (NASDAQ: NKTR ) with Buy rating and $23 price target on strong growth in royalties from recent and future new launches. "In our view, Nektar's ...
- Zacks•3 days ago
Momenta (MNTA) announced that Shire (SHPG) has exercised its right to terminate their collaboration agreement for a biosimilar version of AbbVie (ABBV) Humira.
Shire plc (SHPG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||174.91 x 100|
|Ask||220.00 x 200|
|Day's Range||193.23 - 195.27|
|52wk Range||147.60 - 231.32|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||40.29|
|Avg Vol (3m)||1,111,581|
|Dividend & Yield||0.80 (0.40%)|